Biohaven Pharmaceutical's purchase of a priority review voucher puts rimegepant orally dissolving tablet on track for a potential approval by year-end, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Depending on when the new drug application is filed over the next four months, a rimegepant approval could potentially leapfrog Allergan's (AGN) ubrogepant, says the analyst. He views rimegepant as the "best-in-class oral CGRP" and keeps an Overweight rating on Biohaven with a $75 price target.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Soligenix (SNGX),... To see the rest of the story go to thefly.com. See Story Here